Evidence map›Paper›PMID 42112134›Full record

ArticleJournal of ginseng research2026

Dual-targeted liposomes delivering ginsenoside CK attenuate cerebral ischemia-reperfusion injury by suppressing PANoptosis via O-GlcNAcylation of RIPK1/RIPK3.

Suping Li, Ping Ni, Haifeng Shao, Qiao Chen, Jing Fu, Fei Xu, Chaohui He, Gang Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of ginseng research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Suping LiGraduate School, Dalian Medical University, Dalian, China.
Ping NiDepartment of Neurology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Haifeng ShaoDepartment of Neurology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Qiao ChenDepartment of Neurology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Jing FuDepartment of Rehabilitation, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Fei XuDepartment of Neurology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Chaohui HeThe Affiliated Hospital of Sichuan Nursing Vocational College (the Third People's Hospital of Sichuan Province), Chengdu, China.
Gang LiGraduate School, Dalian Medical University, Dalian, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Ischemic stroke remains a major cause of mortality and disability worldwide, with limited treatment options. This study aimed to develop dual-targeted liposomes containing ginsenoside CK and evaluate their neuroprotective effects against cerebral ischemia-reperfusion injury. Methods: Liposomes modified with transferrin, rabies virus glycoprotein, and ginsenoside CK were prepared and characterized. Their uptake and protective effects were assessed in neuronal and endothelial cells subjected to oxygen-glucose deprivation/reoxygenation (OGD/R). A rat model of transient middle cerebral artery occlusion was used to evaluate neuroprotection Results: The dual-targeted liposomes exhibited enhanced cellular uptake and brain accumulation. They protected against mitochondrial fission and PANoptosis Conclusion: Dual-targeted liposomes containing ginsenoside CK represent a promising therapeutic strategy for cerebral ischemia-reperfusion injury. This approach overcomes blood-brain barrier limitations through targeted delivery. Besides, ginsenoside CK as a liposome component inhibits PANoptosis via enhanced protein O-GlcNAcylation. Further optimization and safety studies are warranted to advance this strategy toward clinical application.

Indexed as

Cerebral ischemia-reperfusion injuryGinsenoside CKLiposomesO-GlcNAcylationPANoptosis

Identifiers

PMID42112134
PMCPMC13149903

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.